prof. MUDr. Věra Čertíková Chábová, Ph.D.
Klinika nefrologie VFN a 1. LF UK
Prof. MUDr. Věra Čertíková Chábová, Ph.D. se narodila se r. 1963. promovala na Fakultě všeobecného lékařství (nyní LF1) Univerzity Karlovy v r.roce 1998.
Po krátkém působení v mimopražských nemocnicích byla v r. 1992 přijata na I. interní kliniku Všeobecné fakultní nemocnice. Po jejím rozdělení na samostatné hematologické a nefrologické pracoviště se stala zaměstnankyní Kliniky nefrologie, kde působí dodnes. Od r. 2009 je zástupkyní přednosty pro výuku.
V letech 1997 a 1998 absolvovala celkem 4 měsíce stáže na Mayo Clinic v Rochesteru, MN v USA, kde spolupracovala na studii o konzervativním léčení stenózy renálních tepen.
V roce 2012 obhájila habilitační práci „Hypertenzní nefropatie“ a stala se docentkou pro obor vnitřní nemoci.
prof. MUDr. Věra Čertíková Chábová, Ph.D. je autorem těchto článků v časopise Postgraduální nefrologie:
Schlaich MP, Bellet M, Weber MA, et al.; PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel‑group, phase 3 trial. Lancet 2022;400:1927–1937.
Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension. Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH).
J Hypertens 2023;41:1874–2071.
Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension. Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens 2023 Jun 21. doi: 10.1097/HJH.0000000000003480. Epub ahead of print.
Ku E, McCulloch CE, Inker LA, et al. Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes. J Am Soc Nephrol 2023;34:385–393.
Rossing P, Caramori ML, Chan JCN, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int 2022;102:990–999.
Chewcharat A, Thongprayoon C, Vaughan LE, et al. Dietary Risk Factors for Incident and Recurrent Symptomatic Kidney Stones. Mayo Clin Proc 2022;97:1437–1448.
Banerjee D, Winocour P, Chowdhury TA, et al. Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD‑UKKA) Guideline 2021. Kidney Int Rep 2022;7:681–687.
Woller SC, Stevens SM, Kaplan D, et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial.
Blood Adv 2021 Oct 18:bloodadvances.2021005808. doi: 10.1182/bloodadvances.2021005808. Online ahead of print.
Schmieder RE, Mahfoud F, Mancia G, et al.; members of the ESH Working Group on Device Based Treatment of Hypertension. European Society of Hypertension position paper on renal denervation 2021.
J Hypertens 2021;39:1733–1741.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020;98(4S):S1–S115.
de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence‑based advances in monitoring and treatment. Kidney Int 2020;98:839–848.
Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020;75:1334–1357.
Walsh M, Merkel PA, Peh CA, et al. Plasma Exchange and Glucocorticoids in Severe ANCA‑Associated Vasculitis. N Engl J Med 2020;382:622–631.
McCallum W, Tighiouart H, Ku E, et al. Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Kidney Int 2019;96:1185–1194.
Flint AC, Conell C, Ren X, et al. Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes. N Engl J Med 2019;381:243–251.
Heerspink HJL, Parving HH, Andress DL, et al., on behalf of the SONAR Committees and Investigators. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double‑blind, randomised, placebo‑controlled trial.
Lancet 2019;393:1937–1947.
Anderson CS, Huang Y, Lindley RI, et al. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open label, blinded endpoint, phase 3 trial.
Lancet 2019 Feb 6. pii: S0140 6736(19)30038 8. doi: 10.1016/S0140 6736(19)30038 8. [Epub ahead of print]
Williams B, Mancia G, Spiering W, et al.
J Hypertens 2018;36:1953–2041.
Liu P, Wysocki J, Souma T, et al.
Novel ACE2‑Fc chimeric fusion provides long‑lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation.
Kidney Int 2018;94:114–125.
Weisbord SD, Gallagher M, Jneid H, et al.
Hermida RC, Ayala DE, Mojón A, Fernández JR.
Sleep‑Time Ambulatory BP Is an Independent Prognostic Marker of CKD. J Am Soc Nephrol 2017.
pii: ASN.2016111186. doi: 10.1681/ASN.2016111186.
Delgado J, Masoli JA, Bowman K, et al.; as part of the Ageing Well Programme of the NIHR School for Public Health Research, England. Outcomes of Treated Hypertension at Age 80 and Older: Cohort Analysis of 79,376 Individuals. J Am Geriatr Soc 2016 Dec 30. doi: 10.1111/jgs.14712. [Epub ahead of print]
Mehta LR, Awdishu L, Davenport A. Phenotype standardization for drug‑induced kidney disease. Kidney Int Advance, online publication, 8 April 2015; doi:10.1038/ki.2015.115
Baigent C, Landray MJ, Reith C, et al., on behalf of the SHARP investigators. The effect of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo‑controlled trial. Lancet 2011, 377:2181–2192.
SHARP Collaborative Group: Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low‑density lipoprotein cholesterol among 9 438 patients with chronic kidney disease. Am Heart J 2010;160:785–794.